BMO Capital Maintains Outperform on Gilead Sciences, Raises Price Target to $94

Benzinga · 10/17 13:56
BMO Capital analyst Evan Seigerman maintains Gilead Sciences (NASDAQ:GILD) with a Outperform and raises the price target from $85 to $94.